The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | MRD negativity using deep sequencing is a major prognostic factor in myeloma
Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the findings of his recent MRD-focused analysis of a large randomized trial for newly diagnosed multiple myeloma (MM) patients treated with lenalidomide, bortezomib and dexamethasone. This revealed that MRD, measured using next-generation sequencing, is a major prognostic factor in MM. Dr Munshi suggests that MRD status can thus inform clinical practice, and calls for MRD to be assessed in every prospective trial. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
